Looks like you’re on the UK site. Choose another location to see content specific to your location
Roche notes success of Avastin as breast cancer treatment
Roche has noted that Avastin (bevacizumab), when administered in with commonly-used chemotherapies, increases the amount of time that passes without the condition becoming worse in people with previously untreated advanced breast cancer.
The company made its assertions following the completion of a phase III study of the drug called RIBBON-2.
Commenting on the data, William Burns, chief executive officer of Roche’s pharmaceuticals division, said that it is “good news” for women with advanced breast cancer because almost all patients require extra therapy after their initial treatment.
He added: “RIBBON-2 is the first phase III study to show that Avastin may also offer benefits in the second-line setting and we look forward to sharing the data with healthcare authorities around the world.”
Data gleaned from the study will be submitted for presentation at a future medical meeting, Roche concluded.
In recent weeks, Roche announced that its CRUISE phase III trial showed that Lucentis (ranibizumab injection) enhanced vision in patients with macular edema caused by retinal vein occlusion.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard